Persephone Biosciences, a preclinical biotech focused on microbiome-based medicines, raised $15 million in seed funding on Tuesday. The company will use the money to advance its trial for oncology ...

Persephone’s score ranks with Stravinsky’s most tautly constructed music—in his best neoclassic style—but as a stage piece, the work has never caught on. Last week in London.

The other way forward, which Persephone is pursuing in parallel, applies microbes therapeutically in cancer treatment, where it is theorized that it could enhance the effect of immunotherapy drugs.

Stephanie Culler, CEO and Co-founder of Persephone Biosciences, which closed a $15 million seed financing round today. Persephone is a synthetic biology company reimagining patient and infant ...

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, is enrolling subjects in its My Baby Biome ...